Amyloid PET pattern with dementia and amyloid angiopathy in Taiwan familial AD with D678H APP mutation.

J Neurol Sci

Department of Neurology, Chang Gung Memorial Hospital, Taoyuan, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan. Electronic address:

Published: March 2019

AI Article Synopsis

  • The D678H mutation in the amyloid precursor protein gene, known as the "Taiwan mutation," is linked to distinctive amyloid deposition patterns and clinical features in Alzheimer's disease.
  • Researchers analyzed brain scans and clinical data from symptomatic and asymptomatic individuals, highlighting early memory impairment and specific amyloid patterns in those with the mutation.
  • Findings suggest that the D678H mutation leads to a greater amyloid burden compared to sporadic Alzheimer's cases, particularly showing high uptake in the occipital area.

Article Abstract

Introduction: The novel D678H amyloid precursor protein (APP) gene mutation has been called the "Taiwan mutation". The study aims to identify amyloid deposition patterns and clinical features associated with this mutation.

Methods: we analyzed the clinical manifestations, brain neuroimages and F-AV-45 positron emission tomography (PET) findings in symptomatic patients and asymptomatic subjects with the autosomal-dominant Alzheimer's disease (AD). We compared the amyloid deposition pattern among 10 patients with genetically-positive familial cognitive decline (CD), 18 patients with sporadic CD, and 19 healthy controls.

Results: The clinical features were the early onset of memory impairment in all 10 patients and cerebral amyloid angiopathy in 3 patients. The characteristic results of brain F-AV-45 PET included the highest standard uptake value ratio (SUVR) in the occipital and cerebellar cortical areas in the genetically-positive CD patients. In subgroup analysis, the familial AD patients had a decreased amyloid SUVR trend in most areas except for cerebellar cortex compared to those with familial mild cognitive impairment.

Conclusion: Our data indicate that the familial D678H gene mutation have resulted in a more potent amyloid burden than in the patients with sporadic AD patients. The high amyloid uptake in the occipital area is characteristic of the specific Taiwan APP gene.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2018.12.039DOI Listing

Publication Analysis

Top Keywords

amyloid
9
patients
9
amyloid angiopathy
8
familial d678h
8
app gene
8
gene mutation
8
amyloid deposition
8
clinical features
8
patients sporadic
8
familial
5

Similar Publications

Background And Objectives: Cerebrovascular reactivity (CVR) represents the ability of cerebral blood vessels to regulate blood flow in response to vasoactive stimuli and is related to cognition in cerebrovascular and neurodegenerative conditions. However, few studies have examined CVR in the medial temporal lobe, known to be affected early in Alzheimer disease and to influence memory function. We aimed to examine whether medial temporal CVR is associated with memory function in older adults with and without mild cognitive impairment (MCI).

View Article and Find Full Text PDF

Case-only designs in longitudinal cohorts are a valuable resource for identifying disease-relevant genes, pathways, and novel targets influencing disease progression. This is particularly relevant in Alzheimer's disease (AD), where longitudinal cohorts measure disease "progression," defined by rate of cognitive decline. Few of the identified drug targets for AD have been clinically tractable, and phenotypic heterogeneity is an obstacle to both clinical research and basic science.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

The Fourth People's Hospital of Chengdu, Chengdu, Sichuan, China.

Background: Apolipoproteins and cortical morphology are closely associated with memory complaints, and both may contribute to the development of Alzheimer's disease.

Method: A total of 97 patients from the University of Electronic Science and Technology (UESTC) (n=42) and the Fourth People's Hospital of Chengdu (FPHC) (n=55) were grouped based on recruitment location, and underwent neuropsychological tests. ApoB, ApoA1, ApoB/ApoA1, plasma Alzheimer's biomarker, apolipoprotein E (ApoE) genotyping, 3T magnetic resonance imaging.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

The Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Israel.

Background: Amyloid beta (Aβ) deposition marks an early stage in the progression of Alzheimer's disease (AD), detectable in-vivo years before symptoms emerge and targeted by recently FDA-approved drugs. This has propelled advancements in understanding, measuring, and treating AD, paving the way for disease prevention in those at risk. However, the psychological impact of disclosing Aβ status to cognitively unimpaired individuals remains underexplored.

View Article and Find Full Text PDF

Background: biomarkers are essential in order to make a diagnosis with a high level of accuracy in patients with cognitive and behavior complaints. However, molecular imaging biomarkers not always provide an answer in daily clinical practice.

Methods: retrospective and descriptive study in patients with Amyloid PET (APscans) implemented according to rational use of this technic, between January 2019-November 2023 in Neurology Department, Infanta Leonor Hospital, Madrid, Spain.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!